Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

Curto-Barredo, Laia; Duran Jordà, Xavier, 1974-; Giménez Arnau, Anna Maria

Inicio
→
Recerca: articles, congressos, llibres
→
Hospital del Mar Research Institute
→
Articles (Hospital del Mar Research Institute)
→
Ver ítem

dc.contributor.author	Curto-Barredo, Laia
dc.contributor.author	Duran Jordà, Xavier, 1974-
dc.contributor.author	Giménez Arnau, Anna Maria
dc.date.accessioned	2018-10-22T07:33:52Z
dc.date.issued	2018
dc.identifier.citation	Curto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G. et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticarial. Br J Dermatol. 2018 Jul;179(1):210-212. DOI: 10.1111/bjd.16379
dc.identifier.issn	0007-0963
dc.identifier.uri	http://hdl.handle.net/10230/35625
dc.format.mimetype	application/pdf
dc.language.iso	eng
dc.publisher	Wiley-Blackwell
dc.relation.ispartof	British Journal of Dermatology. 2018 Jul;179(1):210-2
dc.rights	This is the pre-peer reviewed version of the following article: urto-Barredo L, Spertino J, Figueras-Nart I, Expósito-Serrano V, Guilabert A, Melé-Ninot G. et al. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticarial. Br J Dermatol. 2018 Jul;179(1):210-212., which has been published in final form at http://dx.doi.org/10.1111/bjd.16379. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
dc.subject.other	Urticària -- Tractament
dc.title	Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	http://dx.doi.org/10.1111/bjd.16379
dc.rights.accessRights	info:eu-repo/semantics/openAccess
dc.type.version	info:eu-repo/semantics/acceptedVersion